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Markers of inflammation in men with small
abdominal aortic aneurysm
Duncan J. Parry, MD, FRCS (Gen.Surg),a,b Hamad S. Al-Barjas, MBChB,c Louise Chappell, BSc,c
S. Tawqeer Rashid, PhD, MRCS,a,c Robert A. S. Ariëns, PhD,a and
D. Julian A. Scott, MD, FRCS, FRCSEd, FEBVS,a,c Leeds and Huddersfield, West Yorkshire,
United Kingdom
Background: Markers of inflammation and fibrin turnover are elevated in individuals with a large (>55 mm) abdominal
aortic aneurysm (AAA). Fibrin degradation generates D-dimer, known to possess multiple proinflammatory effects, and
levels are elevated during early AAA development. This study characterized the plasma inflammatory response during
early AAA pathogenesis to determine the effect of D-dimer levels.
Methods:The study compared 75 men with a small AAA (range, 30–54 mm) with 90 age-, sex-, and race-matched controls.
Plasma interleukin-6 (IL-6), complement C3, high-sensitivity C-reactive protein (hsCRP), fibrinogen, and D-dimer
levels were measured.
Results: Mean levels of fibrinogen (2.92 vs 2.59 g/L; P  .003), hsCRP (2.07 vs 1.29 ng/mL; P  .005), and D-dimer
(346.7 vs 120.2 ng/mL; P< .001) were higher in men with a small AAA. These markers correlated with maximum aortic
diameter determined by ultrasound imaging. On multivariate analysis, D-dimer levels were elevated in AAA individuals
independent of smoking, cardiovascular disease (CVD), atherosclerotic risk factors, and inflammatory parameters.
Fibrinogen and hsCRP levels remained elevated after adjustment for these covariates but lost significance when D-dimer
was added to the model.
Conclusion: C-reactive protein and D-dimer levels are elevated during early AAA development. D-dimer levels are most
tightly associated with AAA status, however, and may mediate the observed elevation in acute-phase reactants. ( J Vasc
Surg 2010;52:145-51.)
Clinical Relevance: Plasma markers of inflammation and fibrin turnover are elevated in large (>55 mm) abdominal aortic
aneurysms (AAAs). Fibrin degradation products include D-dimer, which has multiple proinflammatory effects. The
interaction between inflammatory and coagulatory processes remains ill defined during early AAA development. This
case-control study shows levels of C-reactive protein and fibrinogen are elevated in men with small AAAs (range, 30-54
mm). D-dimer levels were most tightly associated with AAA status, however, and may mediate the elevated levels of
acute-phase reactants. Further studies are required to investigate this hypothesis and whether novel therapeutic strategies
to inhibit fibrin turnover slow early AAA growth.Abdominal aortic aneurysm (AAA) pathogenesis is charac-
terized by chronic inflammation and matrix metallopro-
teinase (MMP)-mediated aortic wall destruction.1 Cyto-
kines induce MMP production within the aortic wall,2 and
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doi:10.1016/j.jvs.2010.02.279large AAAs secrete interleukin (IL) 6 into the circula-
tion.3,4 Interleukins stimulate the hepatic transcription of
acute-phase reactants, including fibrinogen5 and C-reactive
protein (CRP).6 Preoperative plasma CRP levels are ele-
vated individuals with a large AAA (55 mm).7 Results
from studies that used intra-aortic sampling, however, sug-
gest that the aneurysm sac does not secrete CRP,4 and
endogenous synthesis is evident in only 25% of explanted
AAA tissue.8 Furthermore, epidemiologic studies suggest
that CRP levels track aneurysm expansion,9,10 providing
evidence that elevated CRP levels represent a secondary
response to aneurysm expansion.
Inflammation and coagulation are closely entwined,
with evidence supporting a bidirectional relationship.11
Complement cascade activation is a key inflammatory com-
ponent12 and strongly associated with coagulation.13 IL-6
stimulates the expression of tissue factor by macrophages,
causing an intravascular prothrombotic stimulus.14 Plasma
markers of fibrin turnover are elevated in large AAAs .15-18
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turnover is present during early AAA development inde-
pendent of smoking, cardiovascular disease (CVD), and
conventional risk factors.19 Fibrin degradation products
include D-dimer, which has multiple proinflammatory ef-
fects, including the transcription of cytokines and acute-
phase reactants.20-22
At present, the interaction between inflammation and
coagulation remains ill defined during early AAA pathogen-
esis. We hypothesized that fibrin turnover might contribute
to the plasma inflammatory response. The aim of this
case-control study was to characterize the plasma inflam-
matory response in men with a small AAA (range, 30-54
mm) and to determine the effect of plasma D-dimer levels.
METHODS
This hospital based case-control study was approved by
the Leeds Teaching Hospitals National Health Service
(NHS) Trust Local Research Ethics Committee (Project
number CA03/088). All study participants provided in-
formed consent according to the protocol approved by the
Leeds NHS Trust Ethics Committee.
Sample size. Inflammatory markers are elevated in
individuals with a large AAA.4,7,15,16 Assuming 50% of
these differences are clinically important for a population
with a small AAA, then 75 AAA individuals and 90 controls
would provide 90% power at the 5% significance level
(  0.05) for all inflammatory markers.
Study participants. The study identified 105 white
men with a small AAA (range, 30-54 mm) from consecu-
tive referrals to the vascular outpatient department. All
were aged 65 years to maximize recruitment (AAA prev-
alence increases with age) and because an AAA is unlikely to
develop over time in an individual with an aorta 30 mm.
The study excluded 10 men (9.5%) because of an underly-
ing malignancy, active inflammatory conditions, oral anti-
coagulant or steroid therapy, or who had undergone recent
surgery or had experienced an acute thrombotic event (3
months). Of the 95 eligible men, 75 (78.9%) agreed to
participate. They were compared with 90 controls who
were recruited on a matched-pair basis (age, sex, and race)
from consecutive new referrals to vascular, general surgical,
and urology outpatient clinics. All controls had an aortic
diameter of 30 mm and were subject to identical exclu-
sion criteria.
Clinical assessment. All participants fasted for 10
hours overnight and were asked to refrain from smoking
during this period. A detailed clinical history was taken and
the medical notes reviewed. Tobacco smoking, alcohol
consumption, drug history, and the presence of atheroscle-
rotic cardiovascular disease, defined as ischemic heart dis-
ease, cerebrovascular disease, or peripheral arterial disease,
were noted. Blood pressure was determined by automated
cuff to the nearest 2 mmHg and taken as the mean of three
readings. Body mass index was calculated as kg/m2. The
waist/hip ratio was calculated as minimal abdominal girth/
maximal protrusion of the hips (cm) at the symphysis pubis.
A 12-lead electrocardiogram was recorded to exclude myo-cardial ischemia or previous silent infarction. Resting ankle-
brachial pressure indices (ABPI) were measured in both
legs using a hand-held 8-MHz Doppler probe (Handydop
SciMed, Bristol, UK).
A 19-gauge needle was used to obtain a sample of
free-flowing venous blood (50 mL) from an antecubital
vein. The sample was transferred to a lithium heparin tube
at room temperature for a plasma lipid profile and the
inflammatory marker high-sensitivity (hs) CRP. Lithium
fluoride was used for the plasma glucose assay and sodium
citrate for all inflammatory markers. For D-dimer, the
sodium citrate tube was precooled and transferred imme-
diately onto ice after venesection.
Ultrasound assessment. B-mode abdominal ultra-
sound imaging (Siemens Sonoline Elegra, SiemensMedical
Systems, Issaquah, Wash) was performed by a single ob-
server in the transverse scan plane. Maximal infrarenal
anteroposterior (APmax) aortic diameter, which correlates
well with 3-dimensional computed tomography,23 was
taken as the mean of two measurements by electronic
calliper. For intrasubject variability, the 95% limits of agree-
ment were  2.3 mm.
Laboratory methods. Room temperature sample
tubes were centrifuged at 3000g (MSE, Sanyo Gallenkamp
PLC, Loughborough, UK) for 20 minutes. Iced samples
were centrifuged at 4000g for 30 minutes in a precooled
centrifuge (Coolspin, Fisons Scientific, Loughborough,
UK) at 4°C. Plasma aliquots were snap frozen in liquid
nitrogen before being placed in long-term storage at
–40°C. All assays were performed in duplicate, and mean
levels were calculated. Plasma fibrinogen was measured on
a KC10 coagulometer (Amelung, Germany) using the
Clauss method. D-dimer (TintElize, Biopool Intl, Umea,
Sweden) and IL-6 (DuoSet, R and D Systems, Minneapo-
lis, Minn) were measured by commercially available en-
zyme-linked immunosorbent assay (ELISA) hsCRP assay.
Complement C3 level was measured by in-house ELISA
using antibodies from DAKOcytomation (Glostrup, Den-
mark). The interassay coefficients of variation for fibrino-
gen, D-dimer, IL-6, hsCRP, and complement C3 were
3.5%, 5.3%, 2.3%, 5.7%, and 11.0%, respectively.
Statistical methods. Data were assessed for normality
using a one-sample Kolmogorov-Smirnov test. Normally
distributed data are presented as mean (standard devia-
tion), log-normal data as geometric mean (antilogged 95%
confidence intervals), non-normally distributed data as me-
dian and interquartile range (IQR; 25th, 75th percentiles)
and categoric data as a proportion (%). An independent t
test was used to assess for a difference in means, Mann-
Whitney U test for a difference in ranks, and 2 test for
difference in proportions between the study groups. For
the plasma inflammatory markers (n  5), to protect
against multiple type 1 error, we considered only values of
P .05 /n to be significant after themethod of Bonferroni.
Bivariable correlation was used to examine the associa-
tion between inflammatory markers and aortic diameter
(APmax). Pearson correlation coefficients () were calcu-
lated if both variables were normally distributed and the
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nonparametric. Multiple linear regression analysis was used
to control for systematic differences between study groups.
Inflammatory markers that were elevated in men with AAA
were entered into a forward-stepwise regression model as
the dependent variable. Case type was added as the first
covariate, and inflammatory marker levels were then se-
quentially adjusted for (1) smoking status, (2) atheroscle-
rotic CVD, (3) conventional risk factors, (4) drug thera-
pies, (5) inflammatory mediators, and (6) D-dimer levels.
All analyses were performed using SPSS 12.0 software
(SPSS Inc, Chicago, Ill). Statistical significance was taken at
the 5% level (  0.05). Sample size was determined using
Power and Precision 3 software (Biostat, Englewood, NJ).
RESULTS
Clinical and biochemical characteristics. The clini-
cal, biochemical, and hemostatic characteristics of the study
groups are reported in Table I. The median (IQR) aortic
diameter in the AAA group was 41 mm (35, 47 mm) vs 20
mm (18, 22 mm) in controls (P .001). Both groups were
similar in terms of age, alcohol intake, anthropometric
characteristics, systolic blood pressure, triglycerides, and
high-density lipoprotein cholesterol levels. The AAA group
had a higher prevalence of atherosclerotic CVD, angioten-
sin-converting enzyme-inhibitor (ACEI) therapy, and an-
tiplatelet therapy. There was significantly higher cumulative
cigarette exposure, prevalence of current smokers, those
with established diabetes, 2-hour glucose, and HbA1c (%)
levels in AAA participants. Total cholesterol and low-density
lipoprotein cholesterol levels were lower in AAA partici-
pants, although a higher proportion was taking statins.
Markers of inflammation. Fibrinogen, hsCRP, and
D-dimer levels were significantly elevated in the AAA group
(Table I); however, there was no difference in C3 or IL-6
levels. On bivariable analysis, hsCRP and fibrinogen levels
both correlated with aortic diameter (Table II); however,
the strongest association was with D-dimer. Significant
correlation between plasma cytokines (IL-6), acute-phase
reactants (hsCRP, fibrinogen), and markers of fibrin deg-
radation (D-dimer) were evident (Table II).
Multiple linear regression analysis
Fibrinogen model. Multiple linear regression analysis
was performed using fibrinogen as the dependent variable
and case type (AAA vs control) as the first covariate. Se-
quential adjustments were made using (1) smoking status
and pack-years smoked; (2) atherosclerotic CVD (vs none)
and the ABPI; (3) total-cholesterol levels, HbA1c (%), and
impaired glucose regulation or diabetes; (4) statin, anti-
platelet, or ACEI therapy (vs none); and (5) inflammatory
mediators (IL-6, C3) as covariates. In this model, fibrino-
gen remained significantly elevated in AAA participants
(2.93 [95%CI, 2.70-3.18] g/L) vs controls (2.61 [95%CI,
2.47-2.75] g/L; P  .020). When D-dimer was added to
the model, the association between AAA status and fibrin-
ogen lost significance (3.04 [95% CI, 2.76 to 3.31] g/L vs
2.79 [95% CI, 2.58 to 3.00] g/L; P  .117). In the finalmodel (Table III), only D-dimer and the ABPI indepen-
dently predicted fibrinogen levels (R2  24.1%).
High-sensitivity CRP model. Plasma levels remained
significantly elevated in AAA participants (2.51 [95% CI,
1.95-3.31] mg/L) vs controls (1.45 [95% CI, 1.10-1.95]
mg/L; P  .005) after adjustment for the confounding
influences of (1) smoking status and pack-years; (2) athero-
sclerotic CVD and ABPI; (3) total-cholesterol levels,
HbA1c (%), and impaired glucose regulation or diabetes;
(4) statin, antiplatelet, or ACEI therapy; and (5) inflamma-
tory mediators (IL-6, C3).With the addition of D-dimer to
the model, the association between AAA status and hsCRP
lost significance (1.70 [95% CI, 1.28-2.29] mg/L) vs
controls (1.59 [95% CI, 1.17-2.12] mg/L; P  .479). In
the final model (Table III) only D-dimer, C3, and IL-6
independently predicted hsCRP levels (R2  24.2%).
D-dimer model. D-dimer levels remained signifi-
cantly elevated in AAA participants after adjustment for (1)
smoking status and pack-years; (2) atherosclerotic CVD
and ABPI; (3) total-cholesterol levels, HbA1c (%), and
impaired glucose regulation or diabetes; (4) statin, anti-
platelet, or ACEI therapy, and (5) inflammatory mediators
(IL-6, C3, hsCRP). In the final model (Table III). case
type, CVD presence, and ACEI therapy independently
predicted D-dimer levels (R2  52.3%).
DISCUSSION
AAA are defined by an aortic diameter 30 mm24 and
effect about 5% of elderly men.25 Aortic diameter predicts
for risk of rupture, which accounts for about 6000 deaths
per annum in England andWales.26 For a small AAA (30 to
54 mm,) risk of rupture is low (about 1% per annum), and
mortality primarily relates to atherosclerotic CVD.27 The
presence of a large AAA (55 mm), however, confers a
significant risk of rupture necessitating repair by surgical or
endovascular intervention.25,28 Notwithstanding repair,
CVD risk remains high in these patients. Inflammatory
processes are of pivotal importance in AAA pathogenesis1
and are closely entwined with coagulation.11 Plasma mark-
ers of inflammation4,7,17 and fibrin turnover are elevated in
individuals with a large AAA (55 mm).15-18
We have recently shown this enhanced systemic state of
fibrin turnover occurs during early AAA development and
cannot be explained by smoking, atherosclerotic CVD, or
conventional risk factors.19 At present, the inflammatory
response remains poorly characterized during the early
AAA development; yet, this represents the optimal stage for
novel therapeutic interventions to delay sac growth.
This study illustrates that men with small AAA (30 to
54 mm) have significantly increased plasma fibrinogen,
hsCRP, and D-dimer levels, supporting the existence of a
generalized proinflammatory state. Indeed, significant cor-
relations between fibrinogen, hsCRP, and D-dimer levels
were noted. These findings are consistent with previous
observations in coronary artery disease, which Lowe et al29
postulated may be mediated by IL-6.29 In our study, aortic
diameter correlated with fibrinogen, hsCRP, and D-dimer
levels as previously documented.8,10,30 The tightest associ-
abetes
fter B
JOURNAL OF VASCULAR SURGERY
July 2010148 Parry et alation was observed for D-dimer, which independently pre-
dicted AAA status and may serve as a stronger marker for
early aneurysm disease.
Isolated studies have measured inflammatory markers
in individuals with small AAA.9,10 These studies, however,
are methodologically limited by (1) lack of a control
group,10 (2) failing to adequately characterize aneurysm
Table I. Clinical characteristics, biochemical risk factors, a
Variables
AA
(n 
Age, mean (SD), ya 72 (7)
Aortic diameter, median (IQR) mmb 41 (35,
Current smoker, No. (%)c 23 (30.6
Pack-years smoked, median (IQR)b 27 (4, 5
Alcohol, median (IQR) U/wkb 5 (0, 1
Atherosclerotic CVD, No. (%)c,d 45 (60.0
PAD, No. (%)c,e 23 (31.1
Diabetes mellitus, No. (%)c 13 (17.3
Hypertension, No. (%)c 31(41.3
DVT/PE, No. (%)c 4(5.3)
Drug therapy, No. (%)
Statinc 35 (46.7
Antiplatelet agentc 37 (49.0
ACEIc 29 (38.7
NSAIDc 1 (1.3)
	-blockerc 15 (20.0
Height, mean (SD) cma 1.70 (0.07
Weight, mean (SD) kga 78.9 (14.5
BMI, mean (SD) (kg/m2)a 26.95 (4.69
Waist, mean (95% CI)f 0.95 (0.94
ABPI right, median (IQR)b 1.00 (0.88
ABPI left, median (IQR)b 0.98 (0.75
SBP, mean (SD) mm Hga 148 (21)
DBP, mean (SD) mm Hga 82 (12)
Serum lipids, mmol/L
Cholesterol
Total, mean (SD)a 4.6 (0.9)
LDL, mean (SD)a 2.7 (0.7)
HDL, median (IQR)b 1.30 (1.00
Triglyceride, mean (95% CI)f 1.5 (1.3-
Glucose, mmol/L
0 hours, median (IQR)b 5.2 (4.8,
2 hours, mean (95% CI)f 6.0 (5.6-
HbA1c median (IQR), %
b 5.8 (5.6,
IGR or diabetes, No. (%)c,g 29 (38.7
IL-6, mean (95% CI) ng/mLf 3.13 (2.60
Complement C3, mean (SD) ng/mLa 1.03 (0.17
HsCRP, mean (95% CI) mg/Lf 2.07 (1.66
Fibrinogen, mean (SD) g/La 2.92 (0.76
D-dimer, mean (95% CI) mg/Lf 346.7 (288
AAA, Abdominal aortic aneurysm; ABPI, ankle-brachial pressure index;
confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pre
HDL, high-density lipoprotein;HsCRP, high sensitive C-reactive protein; IG
LDL, low-density lipoprotein; NSAID, nonsteroidal anti-inflammatory dru
aParametric data analyzed by independent t test.
bNonparametric data analyzed by Mann-Whitney U test.
cCategoric data analyzed by 2 test.
dIschemic heart disease (angina, acute myocardial infarction or abnormal el
ischemic attack, stroke, or known asymptomatic carotid disease).
ePeripheral arterial disease: intermittent claudication or an ABPI  0.9.
fLog10 normal data expressed as geometric mean (antilogged 95% CI) anal
gImpaired fasting glycemia, impaired glucose tolerance, newly diagnosed di
hInflammatory markers (n  5) statistical significance taken at P  .05/n adiameter,9 or (3) failing to comprehensively adjust forconfounding influences.9 We minimized bias in this hospi-
tal case-control study by synchronously recruiting twowell-
characterized study groups that were matched for age, sex,
and race. We concede that an epidemiologic study of
cross-sectional or nested case-control design provides more
robust evidence. Both would require a sizeable study pop-
ulation and have clear implications on cost and duration
flammatory markers in the study groups
Controls
P value(n  90)
72 (6) .517
20 (18, 22) .001
12 (13.3) .017
7 (0, 35) .003
4 (0, 5) .102
32 (35.6) .001
14 (15.5) .044
2 (2.2) .002
22 (24.4) .056
2 (2.2) .285
19 (21.1) .001
30 (32.2) .021
13 (13.3) .000
1 (1.1) .889
13 (14.4) .320
1.71 (0.08) .356
80.2 (12.1) .493
27.32 (5.04) .614
7) 0.95 (0.93-1.03) .645
8) 1.05 (1.01, 1.14) .017
2) 1.04 (0.99, 1.10) .001
146 (20) .698
78 (10) .008
5.0 (0.9) .002
3.0 (1.0) .028
0) 1.30 (1.15, 1.60) .237
1.4 (1.3-1.6) .687
5.4 (4.9, 5.8) .685
5.2 (4.9-5.5) .005
5.6 (5.4, 5.8) .002
20 (22.2) .017
8) 3.14 (2.72-3.62) .979h
1.00 (0.20) .410h
7) 1.29 (1.00-1.64) .005h
2.59 (0.65) .003h
7.5) 120.2 (106.9-134.2) .001h
I, angiotensin-converting enzyme inhibitor; BMI, body mass index; CI,
DVT/PE, deep vein thrombosis/pulmonary embolism; Hb, hemoglobin;
paired glucose regulation; IQR, interquartile range (25th, 75th percentile);
, systolic blood pressure; SD, standard deviation.
ardiogram), peripheral arterial disease, or cerebrovascular disease (transient
y independent t test.
according to World Health Organization criteria, or known diabetes.
onferroni method.nd in
As
75)
46)
)
1)
0)
)
)
)
)
)
)
)
)
)
)
)
-0.9
, 1.0
, 1.0
, 1.7
1.7)
5.9)
6.5)
6.2)
)
-3.7
)
-2.5
)
.5-42
ACE
ssure;
R, im
g; SBP
ectroc
yzed bthat were beyond our financial constraints. Although sys-
oeffici
r  0
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these potentially confounding influences were controlled
for by regression analysis. Of particular interest was the
difference in prevalence of diabetes across study groups:
Firstly, the prevalence of participants with established
diabetes was low in controls, which may reflect volunteer
bias. The presence of newly diagnosed diabetes or impaired
glucose regulation wasmore common in the control group.
Consequently, the overall prevalence of dysglycemia was
about 20%, which for this age group is directly comparable
to the general population.
Secondly, the prevalence of diabetes was high in the
AAA patients. This is at odds with pooled epidemiologic
data suggesting that diabetes has a protective effect against
AAA development.31 The mechanisms that underpin this
protective effect are currently undetermined. One putative
mechanism involves insulin resistance, elevated plasmino-
gen activator inhibitor type 1 levels, and suppressed plas-
min-mediated proteolysis. Alternatively, hyperglycemia leads
Table II. Bivariable association between plasma inflamma
diameter
Variable Log IL-6 C3
APmax
b 0.076 0.128
log IL-6a 1.000 0.085
Complement C3a 0.085 1.000
Log hsCRPa 0.259 0.302
Fibrinogena 0.171 0.197
Log D-dimera 0.173 0.084
APmax, Maximum anteroposterior aortic diameter; hsCRP, high-sensitivity
aWhere both variables are normally distributed, the values presented are Pe
bWhere one or more variable is nonparametric Spearman rank correlation c
P  0.05 where r  0.150, P  .01 where r  0.190, and P  .001 where
Table III. Multiple linear regression analysis—final mode
D-dimer levels
Final model Parameter
Fibrinogen Corrected model
ABPI
Log D-dimer
aAAAs (3.04 [95% CI, 2.76 to 3.31] g/L) vs controls (2.79 [95%
R2  0.241 (adjusted R2  0.212)
Log hsCRP Corrected model
Log D-dimer
Log IL-6
Complement C3
aAAAs (1.70 [95% CI, 1.28 to 2.29] mg/L) vs controls (1.59 [95
R2  24.2 (adjusted R2  21.4)
Log D-dimer Corrected model
Case type
CVD presence
ACEI therapy
aAAAs (320.0 [95% CI 274.5 to 369.8] ng/mL vs controls (119.
R2  52.3 (adjusted RK2  50.8)
AAA, Abdominal aortic aneurysm; CI, confidence interval; hsCRP, high-se
aAdjusted levels of inflammatory markers in AAAs and controls.to the formation of advanced glycation end products.These are known to promote extracellular matrix deposi-
tion cross-linking and inhibit MMP activity. Our study was
small and hospital-based. Consequently, the high preva-
lence of diabetic participants in the AAA group likely re-
flects selection bias. We emphasize, however, that all po-
tential sources of dysglycemic confounding were fully
adjusted for in the regression analysis.
Acute-phase reactants. Greatly elevated levels of acute-
phase response proteins occur during acute infection or
inflammation and are mediated by IL-1 or IL-6.5,6 Mod-
erate elevations reflect chronic hepatic stimulation, al-
though vascular CRP production is now recognized and
may contribute to plasma levels.32,33 Despite this, endog-
enous CRP synthesis is evident in only 25% of AAA ex-
plants.8 Field studies of intraoperative flow that directly
sampled aortic blood show large AAAs do appear to secrete
CRP.4 Furthermore, epidemiologic data show that CRP
levels track aneurysm development.9,10 These studies pro-
vide persuasive evidence that elevated CRP levels represent
markers, fibrin degradation (D-dimer), and aortic
Log hsCRP Fibrinogen Log D-dimer
0.212 0.325 0.658
0.259 0.171 0.173
0.302 0.197 0.084
1.000 0.298 0.317
0.298 1.000 0.337
0.317 0.337 1.000
tive protein; IL, interleukin.
correlation coefficients ().
ents () are given.
.240.
fibrinogen, high-sensitivity C-reactive protein, and
Regression coefficient (95% CI) P value
.001
–.115 (–0.222 to –0.008) .046
0.081 (0.013 to 0.150) .042
.58 to 3.00] g/L; P  .217).
.001
0.294 (0.052 to 0.536) .018
0.330 (0.113 to 0.548) .003
0.755 (0.372 to 1.138) .001
, 1.17 to 2.12 mg/L]; P  .479).
.001
0.426 (0.338 to 0.513) .001
0.214 (0.126 to 0.302) .001

0.108 (–0.210 to –0.006) .038
% CI, 103.3 to 139.6] ng/mL ; P  0.000).
ty C-reactive protein.tory
C-reac
arsonls for
CI, 2
% CI
9 [95
nsitivia secondary hepatic response to aneurysm expansion.
JOURNAL OF VASCULAR SURGERY
July 2010150 Parry et alElevated hsCRP levels in our AAA population support
previous observations in individuals with large AAA.7 Con-
versely, Dawson et al4 failed to demonstrate any differ-
ences, but with only 27 AAAs and 15 controls, their study
was almost certainly subject to type 2 error.4 Elevated CRP
levels have been described in association with smoking,
atherosclerotic disease, and risk factor clustering in the
metabolic syndrome.29,34 CRP levels are elevated in screen-
detected AAA after adjustment for atherosclerosis or smok-
ing.9 Nevertheless, all potential confounders were not in-
cluded in a single regression model, and AAA morphology
was ill defined. We have recruited a well-characterized
study population and adjusted for a comprehensive array of
confounding influences.
In this study, CRP levels remained significantly ele-
vated in participants with AAA after adjustment for smok-
ing, atherosclerotic CVD, conventional risk factors, and
inflammatory mediators (C3 and IL-6). With the addition
of D-dimer to the model, however, this association lost
significance. The same effect was observed when D-dimer
was added to the fibrinogen model. These findings may
indicate that fibrin degradation mediates the increased lev-
els of acute-phase reactants in AAA participants, although
the cross-sectional nature of this study did not allow us to
confirm or refute this hypothesis. D-dimer has multiple
proinflammatory effects, including (1) neutrophil and
monocyte activation, (2) the stimulation of cytokine release
(IL-1 and IL-6), and (3) increased synthesis of hepatic
acute-phase reactants.20-22,35 As a consequence, D-dimer
has a biologically plausible role in governing the hepatic
transcription of acute-phase reactants, although the molec-
ular basis for this remains unclear.
Interleukins. We did not observe any difference in
IL-6 levels between study groups. Interleukin-6 has been
implicated in AAA pathogenesis, with high levels of mes-
senger RNA and protein present in explanted tissue.36
Large AAAs have been reported to secrete IL-6 into the
circulation,3,4 and plasma levels are elevated in these indi-
viduals compared with controls.4,17 The reports cited,
however, measured inflammatory markers in individuals
with aneurysms that were larger than those in the popula-
tion we studied. The IL response may only become signif-
icant during the later stages of AAA development, which
may explain the discrepancies between previous reports and
our findings. Indeed, other studies have found no correla-
tion between levels of IL-6 and AAA size or growth rate in
populations with small AAAs,3 which are in agreement with
our findings.
D-dimer. D-dimer levels remained elevated in individ-
uals with small AAAs after adjustment for smoking, CVD,
atherosclerotic risk factors, and inflammatory markers.
These findings provide unequivocal evidence of enhanced
fibrinolytic activity during early AAA development. These
observations are consistent with individuals with large
AAAs,15-18 where markers of fibrin turnover correlate with
intraluminal thrombus thickness.15 Mounting evidence
suggests the intraluminal thrombus is biologically active
and participates in AAA pathogenesis37 through the se-questration of inflammatory leukocytes and proteolytic en-
zymes.38 The thrombus mass itself continually remodels
with thrombin deposition.39 Conversely, plasmin-mediated
fibrinolysis results in MMP activation38 and the release of
degradation products.18 Continual thrombus remodeling
may, therefore, account for increased D-dimer levels seen
in our population with small AAA. Future studies should be
directed towards intra-aortic sampling to test this hypoth-
esis.
Other factors may influence basal fibrin turnover, how-
ever, including the presence of atherosclerosis.15,40 In this
study we could not fully exclude the presence of subclinical
atherosclerosis by questionnaire, electrocardiogram, and
ABPI alone. Although subclinical atherosclerosis may con-
found our observations, fibrin turnover falls after aneurysm
repair,15,40 which provides further evidence that the aneu-
rysm sac itself drives much of the hemostatic perturbation.
CONCLUSIONS
The presence of elevated CRP and fibrinogen levels
support the existence of a proinflammatory state in men
with small AAAs. D-dimer levels are most tightly associated
with AAA status, however, and fibrin degradation may
mediate the observed elevation in acute phase reactants.
Further studies are required to investigate this hypothesis
and whether novel therapeutic strategies to inhibit fibrin
turnover slow early AAA growth.
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